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Introduction {#sec1}
============

Fanconi anemia (FA) is a recessively inherited, multisystem disorder characterized by congenital anomalies, hematopoietic failure, and cancer predisposition ([@bib32]). Biallelic mutations in one of at least 22 identified FA genes (with the exception of X-linked *FANCB*) result in progressive stem cell attrition in 90% of affected patients ([@bib25]). Human and murine FA hematopoietic stem and progenitor cells (HSPCs) exhibit characteristic susceptibility to DNA-crosslinking agents ([@bib28]) and chronic inflammatory stimulation ([@bib21], [@bib50]), as well as an exaggerated sensitivity to aldehydes when canonical elimination pathways are disabled ([@bib17], [@bib49]). Yet the physiological role of FA proteins in maintaining HSPC pool size remains to be clarified, owing, in part, to a lack of model systems that mimic the spontaneous and progressive hematopoietic failure seen in patients ([@bib17], [@bib56]).

To gain insight into the role of FA proteins during development and understand the origin of HSPC deficits, we recently investigated fetal hematopoietic function in a murine model of FA, observing quantitative hematopoietic deficits at embryonic day 14.5 (E14.5) ([@bib24]). This is consistent with a case report of compromised cord blood clonogenicity and observations of decreased bone marrow progenitor content in young FA patients ([@bib3], [@bib10]). Indeed, rapid proliferation during experimental transplantation of murine FA bone marrow, progenitor proliferation in rapidly dividing FANCD2- and FANCA-depleted human embryonic stem cells ([@bib55]), or primordial germ cell turnover ([@bib38]) all reveal proliferation deficits following replication stress. During development, definitive murine HSPCs experience a rapid 33-fold expansion in the fetal liver (FL) between E12.5 and E16.5 ([@bib13], [@bib39]), after which hematopoietic function transitions to the bone marrow where HSPCs assume a more quiescent postnatal phenotype ([@bib12], [@bib42]).

HSPCs have evolved complex regulatory systems to minimize DNA damage accrued in response to endogenous and exogenous compounds or associated with aging ([@bib4], [@bib15], [@bib33]). The FA pathway appears to shift double-strand-break repair away from the more error-prone non-homologous end-joining (NHEJ) repair pathway ([@bib31], [@bib62]). Components of the alternative homologous combination (HR) pathway are critical to progenitor repair integrity, suggesting that the disruption of the FA pathway would leave the progenitor pool especially vulnerable to damage accrual ([@bib40]). Recent studies further suggest that protective mechanisms are required to balance the physiological replicative stress that coincides with rapid cell division during hematopoietic development ([@bib1], [@bib12], [@bib39]).

Thus, fetal hematopoiesis provides a unique opportunity to test the hypothesis that FA proteins have a physiological, alkylator-independent role in guarding against replication stress during development, preventing attrition in the rapidly cycling fetal HSPC pool ([@bib35], [@bib36]). Our data from *Fancd2*^*−*/*−*^ FL HSPC herein reveal deficits in proliferative fitness and a broad damage response with constitutive activation of p38, but no evidence of the characteristic postnatal p53 response or apoptosis.

Results {#sec2}
=======

*Fancd2*^*−*/*−*^ Fetuses Exhibit Pervasive Developmental Defects and a Deficiency of Fetal Liver HSPCs {#sec2.1}
-------------------------------------------------------------------------------------------------------

To investigate the prenatal role of the FA pathway, we chose a model of *Fancd2* deficiency, a critical component in the coordination of downstream nuclear DNA repair events ([@bib19], [@bib59]). FL cells were obtained from wild-type (WT) and *Fancd2*-deficient embryos from *Fancd2*^*+*/*−*^ timed breeders at 12.5 and 14.5 days post coitum (dpc). We characterized FL HSPCs at each time point by immunophenotypic analysis of ASL (AA4.1^+^SCA1^+^Lin^low/-^) and SLAM (CD150^+^CD48^−^Lin^neg^SCA1^+^) cells ([@bib26], [@bib27], [@bib57]). *Fancd2*^*−*/*−*^ fetuses were present at a sub-Mendelian frequency at both time points, comprising 17.7%--18.7% of the total fetuses ([Figure 1](#fig1){ref-type="fig"}A) but only 9% of weanlings (Q. Zhang, personal communication), indicating an association with both early and late gestational lethality. Notably, *Fancd2*^*−*/*−*^ fetuses often exhibited gross abnormalities such as microcephaly and microphthalmia ([Figure 1](#fig1){ref-type="fig"}B). At 12.5 dpc, *Fancd2*^*−*/*−*^ fetuses exhibited a 51% deficit in FL mass along with a 27% decline in liver cellularity relative to WT ([Figures 1](#fig1){ref-type="fig"}C and 1D). Not surprisingly, the overall number of both ASL and SLAM HSPCs was reduced in *Fancd2*^*−*/*−*^ FL even as their respective frequencies remained comparable with WT ([Figures 1](#fig1){ref-type="fig"}E and 1F). The underlying lack of FL cell expansion is readily apparent at 14.5 dpc. The *Fancd2*^*−*/*−*^ fetuses were 31% smaller ([Figure 1](#fig1){ref-type="fig"}C) and their livers had 64% fewer cells than WT ([Figure 1](#fig1){ref-type="fig"}D), an even more significant proportional deficit than at the earlier time point. Strikingly, by 14.5 dpc the ASL and SLAM hematopoietic stem cell (HSC) frequencies were significantly lower in *Fancd2*^*−*/*−*^ FL compared with WT, comprising 27% and 61%, respectively ([Figures 1](#fig1){ref-type="fig"}I and 1J). Whereas adult *Fancc*^*−*/*−*^ HSPC show an exaggerated susceptibility to inflammation, a Luminex screening of key inflammatory cytokines showed only modest increases in interleukin-6 (IL-6) and IL-4 release from *Fancd2*^*−*/*−*^ ASL FL at 14.5 dpc ([Figure 1](#fig1){ref-type="fig"}K), generally consistent with FA patient immunological profiles ([@bib30]).

*Fancd2*^*−*/*−*^ Fetal Liver HSPCs Are Irreversibly Compromised and Exhibit Characteristic Sensitivity to DNA-Crosslinking Agents {#sec2.2}
----------------------------------------------------------------------------------------------------------------------------------

To assess the hematopoietic progenitor cell content in *Fancd2*^*−*/*−*^ FL, we conducted methylcellulose colony-formation assays from both *Fancd2*^*−*/*−*^ and WT unfractionated FL, with and without the addition of a DNA interstrand crosslinker, mitomycin C (MM-C). At 12.5 dpc, WT and *Fancd2*^*−*/*−*^ FLs formed 77 and 72 colonies on average with no statistical difference ([Figure 2](#fig2){ref-type="fig"}A). In the analyses with FLs at 14.5 dpc, both WT and *Fancd2*^*−*/*−*^ FL formed fewer colonies compared with the FLs at 12.5 dpc. Moreover, *Fancd2*^*−*/*−*^ FL formed significantly fewer colonies than WT, even in the absence of MM-C, consistent with the notion that progenitor depletion occurs in this model unprovoked by exposure to exogenous agents. These findings were exacerbated with MM-C, which reduced output from both WT and *Fancd2*^*−*/*−*^ FL, but more significantly affected formation of *Fancd2*^*−*/*−*^ FL colonies ([Figure 2](#fig2){ref-type="fig"}B). This phenotype persisted into adulthood ([Figure 2](#fig2){ref-type="fig"}C). We next performed serial transplantation assays, injecting unfractionated WT and *Fancd2*^*−*/*−*^ CD45.2 donor FL into congenic CD45.1, sublethally irradiated recipients ([Figure 2](#fig2){ref-type="fig"}D). Primary recipients of *Fancd2*^*−*/*−*^ FL cells exhibited a 22% decrease in peripheral blood donor chimerism at 4 weeks and a 10% decrease in peripheral blood donor chimerism at 14 weeks, compared with WT ([Figure 2](#fig2){ref-type="fig"}E). This proliferation deficit was further aggravated by a second round of transplantation using unfractionated bone marrow from primary transplant recipients, revealing a 73% decrease in peripheral blood donor chimerism at 4 weeks from *Fancd2*^*−*/*−*^ grafts, which persisted through 14 weeks, in comparison with WT ([Figure 2](#fig2){ref-type="fig"}F). Similarly, HSPC-repopulating defects in adult bone marrow can be uncovered with the stress of transplantation, prompting a significant decrease of 42% in *Fancd2*^*−*/*−*^ peripheral blood donor chimerism at 4 weeks and 45% at 16 weeks, compared with WT donor bone marrow ([Figures 2](#fig2){ref-type="fig"}G and 2H). Taken together, our results demonstrate a pervasive developmental defect in *Fancd2*-deficient mice, with a constitutive loss of proliferative capacity and HSC self-renewal that coincides with physiological replication stress during developmental expansion in the FL.

*Fancd2*^*−*/*−*^ FL HSPCs Show Activated DNA-Damage Responses and Accumulation of DNA Strand Breaks {#sec2.3}
----------------------------------------------------------------------------------------------------

Hypothesizing that the DNA replication stress during rapid cell division in FL HSPCs requires FA pathway integrity, we investigated whether DNA-damage response (DDR) elements were activated in *Fancd2*^*−*/*−*^ FL at 14.5 dpc. We assessed the presence of spontaneous double-strand breaks by conducting immunofluorescent labeling of γH2AX in SCA1-enriched FL HSPCs. Although *Fancd2*^*−*/*−*^ FL HSPCs showed a modest increase in the percentage of cells presenting more than five γH2AX foci, no statistical difference between WT and *Fancd2*^*−*/*−*^ FL HSPCs was observed at lower levels of damage ([Figures 3](#fig3){ref-type="fig"}A and 3B). As a validated alternative, we then sought evidence of DNA repair activation by investigating the presence of nuclear RAD51, a protein that binds single-stranded DNA to facilitate homologous strand searching ([@bib37]), and observed a significant increase in the percentage of HSPCs with RAD51 foci in *Fancd2*^*−*/*−*^ FL, compared with WT ([Figures 3](#fig3){ref-type="fig"}C and 3D). Next, we assayed the relative expression of DDR genes in *Fancd2*^*−*/*−*^ and WT FL HSPC. Among SCA1^+^ FL cells, we found a consistent trend for transcriptional upregulation of genes involved in both HR and NHEJ, including *Rad51*, *Xrcc5*, *Xrcc6*, *Xrcc2*, and *Prkdc*, in *Fancd2*^−/−^, although only Prkdc was statistically significant ([Figure 3](#fig3){ref-type="fig"}E). In an additional survey of *Rad51*, *Xrcc2*, and *Prkdc* transcripts in the more highly enriched ASL HSPC population, we found that *Xrcc2* was significantly upregulated, with *Rad51* expression trending upward in *Fancd2*-deficient cells ([Figure 3](#fig3){ref-type="fig"}F). Finally, we sought to corroborate DNA damage in *Fancc*^*−*/*−*^ and *Fancd2*^*−*/*−*^ FL HSPCs via the alkaline comet assay, a measure of single- or double-strand breaks ([@bib5]). Analysis of SCA1-enriched FL HSPCs showed a significant increase in strand breaks in both *Fancc*^*−*/*−*^ and *Fancd2*^*−*/*−*^ FL compared with WT ([Figures 3](#fig3){ref-type="fig"}G--3I). Importantly, cells assayed were not subjected to exogenous stress via interstrand crosslinker exposure. Thus, the aggregate results demonstrate a broad DDR in response to fetal hematopoietic replicative demand in the context of FA pathway deficiency.

*Fancd2*^*−*/*−*^ FL HSPCs Exhibit Constitutive Activation of p53-Independent Downstream Stress Responders {#sec2.4}
----------------------------------------------------------------------------------------------------------

Adult FA HSPCs undergo apoptosis and exhibit a canonical p53 response elicited by exogenous cell stress ([@bib10]). Similarly, under exogenous induction such as irradiation, p53 is phosphorylated in both WT and *Fancd2*^*−*/*−*^ SCA1^+^ FL cells ([Figure 4](#fig4){ref-type="fig"}A). However, in our analyses of total and phosphorylated (Ser15) p53 expression in unperturbed fetal HSPCs, by western blot and phospho-flow cytometry, respectively, we found no major difference between WT and *Fancd2*^*−*/*−*^ FL cells ([Figures 4](#fig4){ref-type="fig"}B--4E). Consistent with this apparent lack of p53 response, we found no evidence of apoptosis in *Fancd2*^*−*/*−*^ HSPCs when we analyzed annexin V staining by flow cytometry and expression of pro-apoptotic p53 target genes, *Puma* and *Noxa* ([Figures 4](#fig4){ref-type="fig"}F and 4G). During the cell-cycle analysis using Ki-67 and Hoechst staining ([Figure 4](#fig4){ref-type="fig"}H), we observed the rapid cell-cycling characteristics of FL with ∼90% of KSL cells out of the quiescent state. However, there was neither checkpoint arrest nor a significant difference in the proportion of cells in each cell-cycle state between WT and *Fancd2*^*−*/*−*^ ([Figure 4](#fig4){ref-type="fig"}I). To further delineate the canonical stress response, we next studied the expression of phosphorylated ataxia telangiectasia mutated (ATM), an upstream kinase of DDR and cell-cycle checkpoint ([@bib8], [@bib22]), by intracellular flow cytometry. In every set of litters we investigated, phospho-ATM was significantly upregulated in *Fancd2*^*−*/*−*^ FL compared with WT FL by 24% on average ([Figures 4](#fig4){ref-type="fig"}J and 4K). Collectively, our findings elucidate a model of compromised proliferation in *Fancd2*^*−*/*−*^ FL HSPC without p53-mediated cell-cycle arrest or apoptosis in response to replication stress.

*Fancd2*^*−*/*−*^ FL Progenitor and Repopulating Defects Are Partially Reversed by p38 MAPK Inhibition {#sec2.5}
------------------------------------------------------------------------------------------------------

Because the experimental induction of cell stress in FA hematopoietic cells prompts expression of p38 mitogen-activated protein kinase (MAPK), which senses DNA damage and maintains HSPC proliferation and self-renewal ([@bib22], [@bib51], [@bib54]), we asked whether *Fancd2*^*−*/*−*^ FL HSPCs also show increased p38 MAPK activation during rapid FL expansion. Here, we used intracellular flow cytometry and immunofluorescence assays ([Figures 5](#fig5){ref-type="fig"}A and 5B) and found significant constitutive activation of p38 MAPK in *Fancd2*^*−*/*−*^ FL compared with WT FL from both methods ([Figures 5](#fig5){ref-type="fig"}C and 5D). We then sought to determine whether p38 MAPK inhibition would rescue proliferation in *Fancd2*^*−*/*−*^ FL HSPCs. First, we investigated hematopoietic output via colony formation in methylcellulose, with and without the addition of the p38 MAPK inhibitors SB203580 and LY2228820. Co-culture with 10 μM SB203580 and 100 nM LY2228820 significantly increased colony formation from *Fancd2*^*−*/*−*^ FL progenitors by 120%, eliminating the difference in colony formation between WT and *Fancd2*^*−*/*−*^ ([Figure 5](#fig5){ref-type="fig"}E). Next, we cultured unfractionated *Fancd2*^*−*/*−*^ and WT FL cells overnight with 10 μM SB203580 or DMSO vehicle control and transplanted them into sublethally irradiated congenic recipient mice. Subsequently, we injected mice with SB203580 or DMSO intraperitoneally, three times weekly, as previously described ([@bib23]) ([Figure 5](#fig5){ref-type="fig"}F). Strikingly, in vivo inhibition of p38 MAPK significantly improved the repopulation of *Fancd2*^*−*/*−*^ FL at the week 4 time point, when engraftment was on a par with WT control recipients ([Figure 5](#fig5){ref-type="fig"}G). At a later time point (week 11), donor chimerism remained similar to that of the early time point. However, statistical significance was lost due to animal deaths potentially caused by the susceptibility of *Fancd2*^*−*/*−*^ FL recipients to the toxicity of DMSO ([Figure 5](#fig5){ref-type="fig"}F). Altogether, our data demonstrate activation of a canonical cell stress pathway in *Fancd2*^*−*/*−*^ FL that is amenable to pharmacological rescue.

Discussion {#sec3}
==========

HSPC function under stress conditions is severely compromised in models with experimentally disabled DDR ([@bib5]), and our data indicate that DNA repair integrity via the FA pathway is required for proper HSPC pool expansion during development. Mechanistically, HSPC depletion in the FL differs from progressive postnatal losses after exposure to exogenous alkylating agents, aldehyde metabolites, or innate immunostimulation ([@bib17], [@bib21], [@bib32], [@bib49], [@bib56]). Accordingly, the moderately severe spontaneous hematopoietic defects observed in *Fancd2* adult mice ([@bib47], [@bib59]) and in FA patients would represent postnatal progression of hematopoietic failure rather than a de novo onset ([@bib3], [@bib10]).

During hematopoietic development in the FL, rapidly cycling HSPCs experience significant replicative stress ([@bib16], [@bib39], [@bib43], [@bib42]). DNA repair integrity is crucial in mitigating replication stress during HSPC pool expansion and maintenance of genome stability ([@bib1], [@bib4], [@bib5], [@bib60]). Our data comparing phenotypes and progenitor frequency of FL HSPCs between 12.5 and 14.5 dpc provide evidence that *Fancd2*-deficient HSPCs fail to adequately expand in the fetal liver, coincident with DNA-damage accumulation and elevated stress response observed at 14.5 dpc. Equivalent ASL and SLAM frequencies, as well as the colony formation by WT and *Fancd2*^*−*/*−*^ HSPCs at 12.5 dpc, indeed suggest that the significant hematopoietic attrition occurs during FL expansion, a narrow time period of heightened replicative demand. At 14.5 dpc, we confirm significant SLAM-HSC deficits and dramatically diminished proliferative capacity during *Fancd2* deficiency, thereby setting the stage for postnatal *Fancd2*^*−*/*−*^ bone marrow HSPC compromise.

The ensuing replication stress during rapid expansion elicits a broad DDR, when *Fancd2*^*−*/*−*^-deficient HSPC accumulate DNA damage and activate p38 MAPK in response to physiological replication demands encountered during development. The lack of a more robust γH2AX phosphorylation seemed initially surprising to us, but has been reported before ([@bib8], [@bib11], [@bib58]). However, a significant accumulation of DNA strand breaks, as well as RAD51 foci, along with the transcriptional elevation of repair genes in the ASL-sorted population clearly indicate the overall activation of DDR in *Fancd2*^*−*/*−*^ HSPCs ([@bib5], [@bib40], [@bib62]). Not surprisingly, the magnitude of DDR was comparatively more modest in *Fancd2*^*−*/*−*^ FL HSPCs than that observed after typical interstrand crosslinker exposure or chronic injury models ([@bib21], [@bib56]). This is entirely consistent with an operational model of diminished, but not eliminated in utero HSPC function, and experimentally supported by fetal deficits in *Fancd2*^*−*/*−*^ that are not due to apoptosis but rather result from diminished proliferative capacity ([@bib1], [@bib52], [@bib60]). Our observations are further consistent with spontaneous developmental deficits that arise during rapid mitotic cycles in *Fancc* and *Fancm* germ cell proliferation ([@bib38], [@bib44]).

Fetal HSPCs display unique molecular and functional properties before they transition postnatally to the definitive adult phenotype ([@bib6]). Although p53 is readily phosphorylated by irradiation in both WT and *Fancd2*^*−*/*−*^ FL HSPCs and active during development in general (reviewed in [@bib41]), our studies reveal that fetal FA HSPC DDRs are independent of p53 activation. This finding diverges from a well-described phenotype in adult FA models ([@bib10], [@bib17], [@bib61]). A recent study shows that the p53 response is indeed linearly correlated with the number of DNA breaks ([@bib34]). Hence, it is conceivable FL HSPCs at 14.5 dpc may not have accumulated enough DNA damage to reach threshold p53 activity to induce apoptosis or cell-cycle arrest. The data consistently show that *Fancd2*^*−*/*−*^ FL cells encounter genomic stress that activates DDR elements during replication, not seen in adult HSPCs ([@bib16]). Similar to a previous report on HSPC development ([@bib45]), we find no accumulation in G~0~, G~1~, or S-G~2~-M cell-cycle phase, suggesting that cell-cycle transit is evenly prolonged, whereby ATM activation is insufficient to activate checkpoints, leaving cell-cycle phase distribution unchanged, even as *Fancd2*^*−*/*−*^ proliferation and repopulation decline.

Others showed that constitutive activation of the p38 MAPK "stress kinase" results in HSPC pool depletion ([@bib4], [@bib23]). Our studies herein not only corroborate activation of p38 MAPK in *Fancd2*^*−*/*−*^ FL cells, but demonstrate rescue of the proliferative capacity after pharmacological p38 MAPK inhibition both in vitro and in vivo ([@bib22], [@bib23]). Although our in vivo treatment with SB203580 in *Fancd2*^*−*/*−*^ FL recipients precluded full evaluation of the long-term effect on HSCs, rescue strategies involving short-term p38 MAPK inhibition or using a more potent and less toxic compound, such as LY2228820 ([@bib9]), might provide a more definitive answer. Yet while several reports and our data imply that p38 MAPK could be a potential therapeutic target to ameliorate hematopoietic failure in FA patients, it is important to consider that this leaves HSPCs vulnerable to DNA-damage accumulation and genomic instability ([@bib2], [@bib7], [@bib18], [@bib48], [@bib51]).

Taken together, we demonstrate that *Fancd2*^*−*/*−*^ mice exhibit a pervasive developmental HSPC defect that echoes the constitutional defects evident at birth in a subset of FA patients. Mechanistically, the data support a model whereby the physiological replication stress in rapidly cycling *Fancd2*^*−*/*−*^ fetal HSPCs spontaneously elicits DNA damage and promotes the activation of p38 MAPK, resulting a diminished proliferative fitness, but without the characteristic postnatal p53-mediated apoptotic response.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

Mice were handled in accordance with OHSU IACUC guidelines. FLs were harvested at 12.5 and 14.5 dpc during timed pregnancies (vaginal plug method) from C57BL/6 *Fancd2*^+/−^ dams ([@bib20]). Fetal tissues were genotyped using the Phire PCR Kit (Thermo Scientific). Bone marrow cells from adult animals were harvested as previously described ([@bib53]).

CFU-c {#sec4.2}
-----

Methylcellulose progenitor assays (Mouse Methylcellulose Complete Media, R&D Systems) were performed according to the manufacturer\'s instructions with unfractionated FL cells plated at a concentration of 20,000 cells/mL. Assays with p38 MAPK inhibition were conducted with 10 μM SB203580 (Calbiochem), 100 nM LY2228820 (Selleckchem), or DMSO vehicle control.

Transplantation {#sec4.3}
---------------

Fetal liver transplants were performed with unfractionated FL cells (8 × 10^5^) by tail-vein injection into sublethally irradiated (750 cGy) congenic CD45.1 recipients. Transplantation assays with in vivo p38 MAPK inhibition were conducted after overnight incubation of unfractionated FL cells with either 10 μM SB203580 (Calbiochem) or DMSO vehicle control; cells were then washed and injected into irradiated recipients. Recipients received either 15 mg/kg SB203580 or DMSO via intraperitoneal injection three times per week as previously described ([@bib23]). For adult bone marrow transplants, 1 × 10^6^ whole bone marrow cells were transplanted into irradiated (750 cGy) CD45.1 recipients. Chimerism analysis was as previously described ([@bib53]).

Flow Cytometry {#sec4.4}
--------------

For the KSL, ASL, and SLAM HSPC analyses, single-cell suspended 2--4 × 10^6^ whole FL cells were washed in fluorescence-activated cell sorting (FACS) buffer (Dulbecco's PBS, 2% fetal bovine serum \[FBS\]) and stained using LIVE/DEAD Fixable Green (Thermo Scientific L23101), cKIT (BioLegend 105819), SCA1 (eBioscience 25-5981-81), AA4.1/CD93 (eBioscience 17-5892-82), CD48 (BioLegend 103422), and CD150 (BioLegend 115925) antibodies, as well as the lineage antibodies: B220 (BD 553090), GR1 (BioLegend 108408), CD3 (BD 555275), CD4 (BD 553653), CD5 (BD 553023), and TER119 (BD 553673) at the manufacturers\' recommended concentrations (excluding MAC1 in FL analyses \[[@bib43]\]). For the cell-cycle analysis, cells were stained for the populations above as well as 20 μL fluorescein isothiocyanate anti-Ki-67 or anti-mouse immunoglobulin G1 (IgG1) (BD 556026) and 0.1 μg/ml Hoechst (Thermo Scientific 62249). For annexin V staining, cells were stained for ASL, 5 μL annexin V (BioLegend 640906), and 1 μg/mL propidium iodide (Molecular Probes P3566) in ANNEXIN binding buffer (10 mM HEPES, 140 mM NaCl, and 2.5 mM CaCl~2~ \[pH 7.4\]). For intracellular staining, KSL stained cells were fixed with 2% paraformaldehyde (PFA), permeabilized with 0.5% saponin, and stained using 0.2 μg PE anti-phospho-ATM (Ser1981) (BioLegend 651203) and 0.2 μg PE rat anti-mouse IgG (BioLegend 406607), or 0.125 μg APC anti-phospho-p38 MAPK (T180/Y182) (eBioscience 17-9078-42) and 0.5 μg APC goat anti-mouse IgG2 (BD 340473), or 1 μg anti-phospho-p53 (Ser15) (Cell Signaling 12571) and 1 μg PE rat anti-rabbit IgG (eBioscience 12-4739-81). Data were collected on a BD FACSCalibur, Canto II, LSR II, or InFlux (BD Biosciences), and analyzed by FlowJo software (TreeStar), using unstained FL cells as the negative controls for gating and anti-IgG-stained cells to normalize the mean fluorescence intensity.

Real-Time qPCR {#sec4.5}
--------------

KSL bone marrow or ASL FL cells were sorted by FACS on BD InFlux. SCA1^+^ cells were isolated from bone marrow and FL using the Mouse PE Selection Kit (STEMCELL Technologies) with PE anti-SCA1 (BD 553336), and placed in Qiazol. Total RNA was purified with the miRNeasy Mini Kit (Qiagen). mRNA was converted to cDNA using SuperScript III First Strand (Invitrogen). Real-time qPCR was performed on StepOne Plus using Power SYBR Green Master Mix (Applied Biosystems). Primer sequences are described in [Table S1](#mmc1){ref-type="supplementary-material"}. *Fancd2*^*−*/*−*^ and WT samples were normalized to *β-actin*, and *Fancd2*^*−*/*−*^ gene expression was compared with WT.

Immunofluorescence {#sec4.6}
------------------

Single-cell suspensions of FL were enriched by immunomagnetic selection for SCA1, as for real-time qPCR. Enriched FL HSPCs were fixed in 2% PFA and cytospun onto slides. Cells were permeabilized with NET buffer with 0.5% Triton X-100 ([@bib14]) and stained with Hoechst (Thermo Scientific 62249) and AF488-conjugated anti-γH2AX (BioLegend, 613407), rabbit anti-mouse RAD51 (Santa Cruz Biotechnology, 8349) followed by Cy3 goat anti-rabbit IgG (Millipore, AP132C) or Cy5-conjugated anti-phospho-p38 (T180/Y182) (eBioscience, 17-9078-42). For γH2AX and RAD51 immunofluorescence, cells were imaged using the Zeiss ApoTome system and images were processed with Zen software (Zeiss). For phospho-p38 immunofluorescence, z-stack images were acquired using the DeltaVision Applied Precision System (GE Healthcare), and the fluorescence intensity of cy5 within the nucleus area of each cell was analyzed with Imaris software (Bitplane).

Comet Assay {#sec4.7}
-----------

FL cells were immunomagnetically enriched for SCA1 and then prepared for alkaline comet assay as previously described ([@bib46]). Agarose-embedded cells were lysed in alkaline conditions overnight at 4°C followed by electrophoresis. Slides were stained with 2.5 μg/mL propidium iodide, imaged on a Zeiss Axioskop 2 Plus microscope, and analyzed with CaspLab software ([@bib29]).

Western Blot {#sec4.8}
------------

FL cells were lysed using RIPA buffer with protease and phosphatase inhibitor cocktail (Thermo Scientific), followed by ultrasonication (Cole Parmer CPX-130). Lysates were prepared in LDS sample buffer (Life Technologies) with 10% β-mercaptoethanol and boiled for 5 min for denaturation. Denatured protein lysates were loaded on 4%--15% Tris-HCl PAGE gel (Bio-Rad) for gel electrophoresis separation (50 min at 200 V) and transfer (overnight at 25 V). Transferred membranes were blocked with 5% non-fat dry milk (Carnation, Nestlé) in Tris-buffered saline with Tween 20 and blotted with anti-GAPDH (1:5,000, Novus Biologicals) and anti-p53 (1:500, Santa Cruz), followed by anti-mouse and anti-rabbit IgG horseradish peroxidase conjugates (Promega). Blots were developed on X-ray film after 5-min exposure to the SuperSignal West Pico Chemiluminescent HRP substrate (Thermo Scientific). For quantification, protein band intensities were analyzed using Image Studio Lite 5.2 (LI-COR).

Luminex Cytokine Profiling {#sec4.9}
--------------------------

FACS-sorted ASL FL cells were cultured in a 96-well plate in HSC medium (Iscove's modified Dulbecco's medium, 15% FBS, 1% penicillin-streptomycin) for 24 hr, and the supernatants were analyzed for cytokines using a mouse Th1/Th2 Luminex panel (eBioscience) which included IL-12, granulocyte macrophage colony-stimulating macrophage (GM-CSF), interferon-γ (IFN-γ), IL-1β, IL-13, IL-18, IL-2, IL-4, IL-5, IL-6, and tumor necrosis factor α (TNF-α). This analysis was performed by the Endocrine Technologies Support Core at the Oregon National Primate Research Center using the manufacturer\'s instructions. In brief, 25 μL cell-culture supernatant was incubated overnight with antibody-coated, fluorescent-dyed capture microspheres specific for each analyte, followed by detection antibodies and streptavidin-phycoerythrin. Washed microspheres with bound analytes were resuspended in reading buffer and analyzed on a Milliplex Analyzer (EMD Millipore) bead sorter with XPonent Software version 3.1 (Luminex). Data were calculated using Milliplex Analyst software version 5.1 (EMD Millipore). Intra-assay coefficients of variation were as follows: IL-1β, 14.2%; IL-2, 10.4%; IL-4, 6.9%; IL-5, 18.1%; IL-6, 5.7%; IL-13, 7.2%; IFN-γ, 25.4%; IL-12, 14.0%; GM-CSF, 24.5%; TNF-α, 3.8%; IL-18, 6.4%. Because all samples were analyzed in a single assay, no inter-assay variation was calculated.

Statistical Analysis {#sec4.10}
--------------------

All numerical results shown are expressed as mean ± SEM. Two-tailed Student\'s t tests were performed for statistical analyses, unless otherwise stated in the figure legends. A p value of less than or equal to 0.05 was considered significant.
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(G--J) Characterizations of WT and *Fancd2*^*−*/*−*^ fetal mice at 14.5 dpc: fetus weight (p = 0.04, n = 7 WT and 8 KO from five litters), liver cellularity (p = 0.001, n = 7 WT and 14 KO from five litters), percentage of ASL HSPCs (p = 0.03, n = 10 WT and 11 KO from five litters), and percentage of SLAM HSCs in live FL cells (p = 0.01, n = 4 WT and 3 KO from two2 litters).\
(K) Cytokine profiling of ASL-sorted WT and *Fancd2*^*−*/*−*^ unfractionated FL cells (n = 3 WT and 5 KO from two litters; samples that yielded lower than the detection threshold are excluded, hence a statistical test could not be performed).\
Error bars reflect SEM, and asterisks indicate ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, and ^∗∗∗^p ≤ 0.001. n.s., not significant.](gr1){#fig1}

![Defects in *Fancd2*^*−*/*−*^ HSPC Frequency and Repopulating Capacity Persist from Fetal Development through Adulthood\
(A) Colony-forming units per 20,000 unfractionated FL cells at 12.5 dpc (n = 5 WT and 3 KO from two litters).\
(B) Colony-forming units per 20,000 unfractionated FL cells at 14.5 dpc with different doses of mitomycin C treatment (p \< 0.05 between WT and *Fancd2*^*−*/*−*^ at each concentration of MM-C, n = 5--6 WT per condition and 4--6 KO per condition from five litters).\
(C) Colony-forming units per 20,000 adult whole bone marrow cells (n = 2 WT and 4 KO).\
(D) Schema for FL transplantation into primary and secondary recipients. For the primary, each FL donor was transplanted into three recipients (donor n = 2 WT and 4 KO FLs from two litters). In the subsequent transplantation, bone marrow from two WT to three KO primary recipients were injected into three recipients per donor.\
(E) CD45.2 chimerism in peripheral blood of primary recipients at 4 weeks (p = 0.02) and 14 weeks (p = 0.006) post transplant.\
(F) CD45.2 chimerism in peripheral blood of secondary recipients at 4 weeks (p \< 0.001) and 14 weeks (p = 0.02) post transplant.\
(G) Transplantation schema for adult bone marrow cells. Each donor was transplanted into five recipients (donor n = 2 WT and 2 KO).\
(H) CD45.2 chimerism in peripheral blood (p \< 0.001 at both time points).\
Error bars reflect SEM, and asterisks indicate ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, and ^∗∗∗^p ≤ 0.001.](gr2){#fig2}

![DNA-Damage Responses Are Induced, and the Strand Breaks Are Accumulated in FA FL HSPCs\
(A) Representative γH2AX foci in SCA1^+^ FL cells (60× objective lens; the scale bar represents 5 μm).\
(B) Quantification of γH2AX foci per cell (n = 3 WT and 3 KO from three litters).\
(C) Representative RAD51 foci in SCA1^+^ FL (60× objective lens; the scale bar represents 5 μm).\
(D) Quantification of cells positive for foci (p = 0.02, n = 6 WT and 6 KO from three litters).\
(E) Expression of DDR genes in SCA1^+^ FL cells (p = 0.08, 0.44, 0.06, 0.22, and 0.005, respectively; n = 4 WT and 4 KO from three litters).\
(F) Expression of selected DDR genes in ASL-sorted FL cells (p = 0.08, 0.5, 0.04 respectively; n = 3 WT and 3 KO from two litters).\
(G) Olive tail moment of 428 SCA1^+^ FL cells from seven WT animals and 288 SCA1^+^ FL cells from five *Fancc*^*−*/*−*^ animals from four litters (p = 0.003).\
(H) Olive tail moment of 289 SCA1^+^ FL cells from five WT animals and 267 SCA1^+^ FL cells from five *Fancd2*^*−*/*−*^ animals from four litters (p = 0.04).\
(I) Representative alkaline comets of SCA1^+^ FL cells (20× objective lens; the scale bar represents 20 μm).\
Error bars reflect SEM, and asterisks indicate ^∗^p ≤ 0.05 and ^∗∗^p ≤ 0.01.](gr3){#fig3}

![FA Fetal HSPC Attrition Is Not Associated with p53-Mediated Apoptosis or Cell-Cycle Arrest\
(A) Representative histogram showing the activation of phospho-p53 (ser15) after 5 Gy irradiation in WT and *Fancd2*^*−*/*−*^ FL, respectively, compared with the non-irradiated controls.\
(B) Immunoblots for p53 and GAPDH from whole FL lysates (bands are representative of multiple experiments, n = 3).\
(C) Densitometry of p53 protein bands from *Fancd2*^*−*/*−*^ whole FL compared with WT, normalized to GAPDH (p = 0.78, n = 7 WT and 4 KO from 3 litters).\
(D) Representative histogram showing the intracellular staining of phospho-p53 (ser15) in WT and *Fancd2*^*−*/*−*^ SCA1^+^ FL cells.\
(E) Expression of phospho-p53 (ser15) in WT and *Fancd2*^*−*/*−*^ SCA1^+^ FL cells as the mean frequency of intensity (p = 0.16, n = 5 WT and 3 KO from two litters).\
(F) Percentage of ASL cells positive for annexin V (p = 0.75, n = 5 WT and 5 KO from two litters).\
(G) Expression of *Puma* and *Noxa* in WT and *Fancd2*^*−*/*−*^ ASL FL cells by real-time qPCR (p = 0.02 and 0.16, respectively; n = 3 WT and 3 KO from two litters).\
(H) Representative histogram and dot plot demonstrating Hoechst and Ki-67 staining for the cell-cycle analysis of *Fancd2*^*−*/*−*^ KSL FL.\
(I) Comparison between WT and *Fancd2*^*−*/*−*^ FL KSL cells in G~0~, G~1~, and G~2~-M-S phases of the cell cycle (n = 11 WT, 8 KO from four litters).\
(J) Representative histogram showing the intracellular staining of phospho-ATM (Ser1981) in WT and *Fancd2*^*−*/*−*^ KSL FL cells.\
(K) Expression of phospho-ATM (Ser1981) in WT and *Fancd2*^*−*/*−*^ KSL FL cells as the mean frequency of intensity (p = 0.03, data were paired by the litter for t test; n = 2 WT, 1 KO in litter 1; n = 3 WT, 1 KO in litter 2; n = 1 WT, 2 KO in litter 3).\
Error bars reflect SEM and asterisks indicate ^∗^p ≤ 0.05. N.S., not significant.](gr4){#fig4}

![Inhibiting Constitutively Activated p38 MAPK Increases Clonogenicity in *Fancd2*^*−*/*−*^ FL\
(A) Representative histogram showing the intracellular staining of phospho-p38 MAPK (T180/Y182) in WT and *Fancd2*^*−*/*−*^ KSL FL cells.\
(B) Expression of phospho-p38 MAPK (T180/Y182) in WT and *Fancd2*^*−*/*−*^ KSL FL cells as the mean frequency of intensity (p = 0.03, n = 4 WT and 4 KO from two litters).\
(C) Representative images showing the immunofluorescence staining of phospho-p38 MAPK (T180/Y182) in WT and *Fancd2*^*−*/*−*^ SCA1^+^ FL cells (60× objective lens; the scale bar represents 5 μm).\
(D) Immunofluorescence intensity of phospho-p38 MAPK (T180/Y182) in WT and *Fancd2*^*−*/*−*^ SCA1^+^ FL cells (p = 0.003, n = 5 WT and 4 KO from three litters).\
(E) WT and *Fancd2*^*−*/*−*^ colony-forming hematopoietic progenitor cell frequency with and without p38 MAPK inhibitors, 10 μM SB203580, and 100 nM LY2228820 (p ≤ 0.001 between WT and *Fancd2*^*−*/*−*^ at baseline with DMSO, p ≤ 0.001 between *Fancd2*^*−*/*−*^ baseline and both inhibitor conditions, n = 4--10 FL per condition from nine litters).\
(F) Schema for transplantation of FL cells and p38 MAPK inhibitor treatment.\
(G) CD45.2 chimerism in peripheral blood of FL recipients with or without SB203580 treatment at 4 weeks post transplant (p = 0.03, one-tailed t test between DMSO- and SB-treated *Fancd2*^*−*/*−*^ recipients; n = 4 WT + DMSO, 4 WT + SB, 11 KO + DMSO, 10 KO + SB).\
(H) CD45.2 chimerism in peripheral blood of FL recipients with or without SB203580 treatment at 11 weeks post transplant (n = 3 WT + DMSO, 4 WT + SB 5 KO + DMSO, 4 KO + SB).\
Error bars reflect SEM, and asterisks indicate ^∗^p ≤ 0.05 and ^∗∗∗^p ≤ 0.001. N.S., not significant.](gr5){#fig5}

[^1]: Present address: Randall Children\'s Hospital, Portland, OR 97227, USA

[^2]: Present address: MRC Laboratory of Molecular Biology, Protein & Nucleic Acids Division, Cambridge CB2 0QH, UK

[^3]: Present address: Molecular, Cellular, and Structural Biology, University of Minnesota, Minneapolis, MN 55455, USA
